Related Experiment Video
Updated: Jul 1, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
Comparative studies of glatiramer acetate and interferon beta
Abstract:
Over the last decade and a half, several disease-modifying therapies (DMTs) have been approved for the treatment of multiple sclerosis (MS) including glatiramer actetate (GA; Copaxone), interferon beta (IFNB)-1a (Avonex, Rebif), IFNB-1b (Betaferon/Betaseron), mitoxantrone (Novantrone), and natalizumab (Tysabri). Randomized controlled trials (RCTs) of each of these DMTs have demonstrated that treatment has a favourable impact on at least one (often several) of the short-term outcome measures typically used to assess efficacy in MS clinical trials. These outcomes include clinical measures of disease activity such as the number or frequency of relapses, the time to first relapse, etc. They also include clinical measures of disease severity such as disease progression on the Expanded Disability Status Scale (EDSS) or the MS Functional Composite score (MSFC), determined either as a confirmed change over a 3 to 6 month interval or as a total change over the entire duration of the trial, in addition to various magnetic resonance imaging (MRI) measures such as the number and volume of T2 lesions, the number and volume of new or gadolinium (Gd)-enhancing lesions, or the number and volume of T1 dark lesions.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Bioequivalence studies: Biowaivers
Drug Products: Biologics, Biosimilars and Interchangeables
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Bioequivalence: Overview